A novel potential effective strategy for enhancing the antitumor immune response in breast cancer patients using a viable cancer cell-dendritic cell-based vaccine
A novel potential effective strategy for enhancing the antitumor immune response in breast cancer patients using a viable cancer cell-dendritic cell-based vaccine
复制标题
DOI：
10.3892/ol.2018.8631
复制
发表时间：
2018-07-01
期刊：
影响因子：
2.9
通讯作者：
El-Houseini, Motawa E.
中科院分区：
文献类型：
--
作者：
Abdellateif, Mona S.;Shaarawy, Sabry M.;El-Houseini, Motawa E.
树突状细胞（dc）已被用于许多癌症免疫治疗的临床试验；然而，它们在实体瘤中取得的成功有限。因此，本研究的目的是通过体外优化一种可行的基于dc的疫苗，为乳腺癌患者确定一种新的潜在免疫治疗靶点。用活的MCF-7乳腺癌细胞诱导未成熟的dc，并通过流式细胞术检测CD83、CD86和主要组织相容性复合体(MTIC)-II的表达，以及不同T细胞亚群，即CD4(+) T细胞、CD8(+)T细胞和CD4(+)CD25（+）叉头盒蛋白3 (Foxp3)（+）调节性T细胞（Tregs），来评估dc的活性和成熟度。除逆转录定量聚合酶链反应外，还采用酶联免疫吸附法（ELISA）检测Foxp3水平。ELISA法检测大鼠血清白细胞介素-12 （IL-12）、干扰素- γ (ifn - γ)水平。最后，通过酶联免疫吸附法测定乳酸脱氢酶（LDH）释放量，评价细胞毒性T淋巴细胞（ctl）的细胞毒性。结果表明CD83（+）、CD86（+）和MHC-II+。dc显著升高(P
Dendritic cells (DCs) have been used in a number of clinical trials for cancer immunotherapy; however, they have achieved limited success in solid tumors. Consequently the aim of the present study was to identify a novel potential immunotherapeutic target for breast cancer patients through in vitro optimization of a viable DC-based vaccine. Immature DCs were primed by viable MCF-7 breast cancer cells and the activity and maturation of DCs were assessed through measuring CD83, CD86 and major histocompatibility complex (MTIC)-II expression, in addition to different T cell subpopulations, namely CD4(+) T cells, CD8(+ )T cells, and CD4(+)CD25(+) forkhead box protein 3 (Foxp3)(+) regulatory T cells (Tregs), by flow cytometric analysis. Foxp3 level was also measured by enzyme-linked immunosorbent assay (ELISA) in addition to reverse-transcription quantitative polymerase chain reaction. The levels of interleukin-12 (IL-12) and interferon-gamma (IFN-gamma) were determined by ELISA. Finally, the cytotoxicity of cytotoxic T lymphocytes (CTLs) was evaluated through measuring lactate dehydrogenase (LDH) release by ELISA. The results demonstrated that CD83(+), CD86(+) and MHC-II+. DCs were significantly elevated (P